Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D known ✓ | P25100 | 13/20 | 0.38 |
| ▸ | ADRA1A known ✓ | P35348 | 13/20 | 0.38 |
| ▸ | ADRA1B known ✓ | P35368 | 13/20 | 0.38 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.36 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.36 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.36 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.36 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.36 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.36 |
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL29120481 | 1.00 | ADRA1D (0.38) | ADRA1DADRA1AADRA1BSCN1ASCN2A | |
| Tartaric Acid SCHEMBL29358996 | 1.00 | ADRA1D (0.38) | ADRA1DADRA1AADRA1BSCN1ASCN2A | |
| Cadaverine Tartrate SCHEMBL13730985 | 1.00 | ADRA1D (0.38) | ADRA1DADRA1AADRA1BSCN1ASCN2A | |
| Cadaverine Tartrate SCHEMBL28639321 | 1.00 | ADRA1D (0.38) | ADRA1DADRA1AADRA1BSCN1ASCN2A | |
| SCHEMBL16422049 | 0.96 | ADRA1D (0.40) | ADRA1DADRA1AADRA1BSCN1ASCN2A | |
| SCHEMBL6597896 | 0.96 | ADRA1D (0.40) | ADRA1DADRA1AADRA1BSCN1ASCN2A | |
| SCHEMBL1822655 | 0.96 | ADRA1D (0.40) | ADRA1DADRA1AADRA1BSCN1ASCN2A | |
| SCHEMBL17516024 | 0.89 | ADRA1D (0.39) | ADRA1DADRA1AADRA1BSCN1ASCN2A | |
| SCHEMBL13729910 | 0.88 | ADRA1D (0.40) | ADRA1DADRA1AADRA1BDRD3ADRB2 | |
| SCHEMBL22728212 | 0.87 | ADRA1D (0.33) | ADRA1DADRA1AADRA1BSCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111116448-B | Preparation method of indole derivative | 北京鑫开元医药科技有限公司 | 2022-01-04 | — | — | CN | claimed |
| CN-111116448-A | Preparation method of indole derivative | 北京鑫开元医药科技有限公司 | 2020-05-08 | — | — | CN | claimed |
| CN-116242919-A | Detection method of palladium element in silodosin bulk drug and preparation thereof and application of detection method | 上海硕方医药科技有限公司 | 2023-06-09 | — | — | CN | disclosed |
| CN-111116448-B | Preparation method of indole derivative | 北京鑫开元医药科技有限公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-111116448-A | Preparation method of indole derivative | 北京鑫开元医药科技有限公司 | 2020-05-08 | — | — | CN | disclosed |
| US-9932308-B2 | Method for producing indoline compound | UBE INDUSTRIES, LTD. (JP) | 2018-04-03 | — | — | US | disclosed |
| US-20170197917-A1 | METHOD FOR PRODUCING INDOLINE COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2017-07-13 | — | — | US | disclosed |
| EP-3103794-A1 | METHOD FOR PRODUCING INDOLINE COMPOUND | UBE Industries, Ltd. (JP) | 2016-12-14 | — | — | EP | disclosed |
| WO-2012147107-A2 | NOVEL & IMPROVED PROCESSES FOR THE PREPARATION OF INDOLINE DERIVATIVES AND ITS PHARMACEUTICAL COMPOSITION | MSN LABORATORIES LIMITED (IN) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012147019-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF SILODOSIN | ORCHID CHEMICALS AND PHARAMCEUTICALS LIMITED (IN) | 2012-11-01 | — | — | WO | disclosed |
| US-20040235932-A1 | Ophthalmic pharmaceutical compositions | Outdoor Wireless Networks LLC | 2004-11-25 | — | — | US | disclosed |
| EP-1415666-A1 | MEDICINAL COMPOSITIONS FOR OPTHALMIC USE | Kissei Pharmaceutical Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1057813-B1 | INDOLE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | KISSEI PHARMACEUTICAL (JP) | 2004-04-21 | — | — | EP | disclosed |
| US-6310086-B1 | PREVENTION OR TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2001-10-30 | — | — | US | disclosed |
| EP-1057813-A1 | INDOLE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Kissei Pharmaceutical Co., Ltd. (JP) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170197917-A1 | METHOD FOR PRODUCING INDOLINE COMPOUND | INMT, TPH1, INPP5A | ADRA1D 809/4885ADRA1A 847/4885ADRA1B 817/4885 |
| US-20040235932-A1 | Ophthalmic pharmaceutical compositions | ADRA1A, ADORA1, ADRA1D | ADRA1D 3/4885ADRA1A 1/4885ADRA1B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.